
The 50 cancers under the umbrella of soft tissue sarcoma are marked by genetic chaos, and a growing understanding of these mutations may lead to new treatments.

The 50 cancers under the umbrella of soft tissue sarcoma are marked by genetic chaos, and a growing understanding of these mutations may lead to new treatments.

In clinical trials, melanoma remains a ripe discovery ground for the application and combination of immunotherapies and targeted drugs.

In the oncology world, gastrointestinal cancers may be the next in line to realize the promise of immunotherapy.

New treatments, such as immunotherapy, are continuing to prove successful for patients with glioblastoma, one of the most dangerous cancers.

Targeted drugs, as well as immunotherapies, are beginning to change the treatment outlook for people with advanced non-small cell lung cancer.

Angelina Jolie has highlighted the benefits of genetic testing and surgery to prevent hereditary breast cancer, but women must also consider the risks.

For adults with acute leukemia, CAR T cell immunotherapies, targeted drugs and pediatric chemotherapy regimens are improving outcomes.

By empowering the body to fight breast and renal cancers, immunotherapies are poised to improve the treatment landscape.